Durata Therapeutics Inc (DRTX) 24.16 $DRTX
Merger Arbitrage Mondays - November 24, 2014
Asif Suria - at Seeking Alpha - Mon Nov 24, 4:38AM CST
Merger Activity decreased last week with five new mergers announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00), MONT: 22.59 (+0.26), CHYR: 2.81 (+0.01), TDY: 101.36 (-2.07), QRE: 14.35 (-0.50), HAL: 37.93 (-0.30), BBEP: 8.12 (-0.67), AGN: 208.47 (-2.67), LPDX: 5.24 (-0.01), BOLT: 21.99 (+0.01), VYFC: 19.75 (-0.01), BNCN: 16.46 (-0.42), LH: 101.92 (-2.08), OPLK: 24.20 (+0.01), BHI: 54.99 (-0.78)
ArQule (ARQL) Shows Strength: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:39AM CST
ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day.
DRTX: 24.16 (+0.41), LCI: 43.58 (-0.46), ARQL: 1.25 (unch), BIOD: 1.38 (-0.03)
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as its shares rose over 6% on the day.
DRTX: 24.16 (+0.41), LCI: 43.58 (-0.46), ESPR: 37.48 (-1.00), BIOD: 1.38 (-0.03)
PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics
PR Newswire - Tue Nov 18, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that in connection with the acquisition of Durata Therapeutics, Inc. by Actavis, PDL has received approximately $42.7 million in connection with the termination of PDL's credit agreement with Durata, which included repayment of the full principal amount outstanding of $40 million, accrued interest, and prepayment and change of control premiums. In October 2013, PDL entered into a structured financing transaction with Durata in which PDL agreed to provide Durata with up to $70 million of debt financing with a five year term and in turn would receive interest on the principal amount outstanding and a security interest in substantially all of Durata's assets.
DRTX: 24.16 (+0.41), PDLI: 7.41 (-0.08)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), MRK: 57.72 (-1.62), VRX.TO: 160.64 (+0.46)
Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:00AM CST
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 24.16 (+0.41), ZTS: 41.77 (-1.11), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18)
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
PR Newswire - Mon Nov 17, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. As previously announced, Actavis offered to purchase all outstanding shares of Durata for $23.00 per share in cash, or approximately $675 million in the aggregate, and one contingent value right (CVR) per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata's lead product DALVANCETM are achieved.
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), IRWD: 15.00 (+0.09), CBST: 96.31 (+0.04), PFE: 30.95 (-0.70)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), MDT: 72.52 (-1.25), SLXP: 103.36 (-2.79), SNY: 45.16 (-1.05)
Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), SWKS: 69.10 (-0.98), AKRX: 41.24 (+0.38), JAZZ: 165.12 (-8.09), SLXP: 103.36 (-2.79), AAPL: 109.73 (-1.89), ATHM: 36.03 (-0.09)
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata
PR Newswire - Fri Oct 31, 3:15PM CDT
Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
with respect to Actavis' pending acquisition of Durata.
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Durata Therapeutics, Inc. -- DRTX
GlobeNewswire - Wed Oct 29, 1:02PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Illinois Circuit Court on behalf of all common stockholders of Durata Therapeutics, Inc. ("Durata" or the "Company" (Nasdaq
RTX) opposing the proposed acquisition of Durata by Actavis plc ("Actavis" .
DRTX: 24.16 (+0.41)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis
Business Wire - Tue Oct 14, 11:37AM CDT
Levi & Korsinsky is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or "the Company" (NASDAQ: DRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Actavis (NYSE:ACT).
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of the Company
Business Wire - Sat Oct 11, 6:05AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc. ("Durata" or the "Company" (Nasdaq: DRTX) relating to the proposed acquisition by Actavis plc.
DRTX: 24.16 (+0.41)
DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics Inc. (DRTX) Over the Proposed Sale of the Company to Actavis plc (ACT)
PR Newswire - Fri Oct 10, 5:45PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or the "Company" (NasdaqGM: DRTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Actavis plc for approximately $675 million. The Company's stockholders will only receive $23.00 for each share of Durata common stock they own, when according to Yahoo! Finance at least one analyst has set a price target of $26.00 for the Company. The deal price might be $5.00 higher based on a contingency-milestone basis.
DRTX: 24.16 (+0.41)
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Fri Oct 10, 4:31PM CDT
Rigrodsky & Long, P.A.:
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Oct 10, 4:25PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Durata Therapeutics, Inc. (NASDAQ: DRTX), ("Durata" or the "Company" relating to the proposed buyout of the Company by Actavis plc ("Actavis" .
DRTX: 24.16 (+0.41)
Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)
GlobeNewswire - Fri Oct 10, 1:04PM CDT
Durata Therapeutics (Nasdaq RTX) today announced a summary of presentation data from its recently launched product, DALVANCE(TM) (dalbavancin) for injection. The data were presented in five posters at IDWeek 2014, which took place from October 8-11, 2014 in Philadelphia, PA. Among the findings, a study of pharmacokinetic activity in bone and associated tissues demonstrated that dalbavancin accumulates in bone and supports further study in patients with osteomyelitis and prosthetic joint infections. A separate analysis showed patients with ABSSSI who were treated with dalbavancin had similar clinical success rates to those treated with IV vancomycin alone, as well as a tendency to have fewer adverse events and less nephrotoxicity compared to patients who received IV vancomycin for greater-than or equal to10 days. An examination of ASO and DNase-B titers in patients with streptococcal skin infections in the dalbavancin DISCOVER program was also presented.
DRTX: 24.16 (+0.41)
Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 2:52PM CDT
Healthcare companies have been completing merger and acquisitions this year at record pace to counter ongoing patent cliff troubles, as well as political gridlock in the U.S. over corporate tax reform. Activist investor Bill Ackman and his hedge...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), VRX: 138.71 (-0.18), ACT: 259.00 (-4.00), SLXP: 103.36 (-2.79)
Merger Arbitrage Mondays - November 24, 2014
Asif Suria - at Seeking Alpha - Mon Nov 24, 4:38AM CST
Merger Activity decreased last week with five new mergers announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00), MONT: 22.59 (+0.26), CHYR: 2.81 (+0.01), TDY: 101.36 (-2.07), QRE: 14.35 (-0.50), HAL: 37.93 (-0.30), BBEP: 8.12 (-0.67), AGN: 208.47 (-2.67), LPDX: 5.24 (-0.01), BOLT: 21.99 (+0.01), VYFC: 19.75 (-0.01), BNCN: 16.46 (-0.42), LH: 101.92 (-2.08), OPLK: 24.20 (+0.01), BHI: 54.99 (-0.78)
ArQule (ARQL) Shows Strength: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:39AM CST
ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day.
DRTX: 24.16 (+0.41), LCI: 43.58 (-0.46), ARQL: 1.25 (unch), BIOD: 1.38 (-0.03)
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as its shares rose over 6% on the day.
DRTX: 24.16 (+0.41), LCI: 43.58 (-0.46), ESPR: 37.48 (-1.00), BIOD: 1.38 (-0.03)
PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics
PR Newswire - Tue Nov 18, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that in connection with the acquisition of Durata Therapeutics, Inc. by Actavis, PDL has received approximately $42.7 million in connection with the termination of PDL's credit agreement with Durata, which included repayment of the full principal amount outstanding of $40 million, accrued interest, and prepayment and change of control premiums. In October 2013, PDL entered into a structured financing transaction with Durata in which PDL agreed to provide Durata with up to $70 million of debt financing with a five year term and in turn would receive interest on the principal amount outstanding and a security interest in substantially all of Durata's assets.
DRTX: 24.16 (+0.41), PDLI: 7.41 (-0.08)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), MRK: 57.72 (-1.62), VRX.TO: 160.64 (+0.46)
Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:00AM CST
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 24.16 (+0.41), ZTS: 41.77 (-1.11), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18)
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
PR Newswire - Mon Nov 17, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. As previously announced, Actavis offered to purchase all outstanding shares of Durata for $23.00 per share in cash, or approximately $675 million in the aggregate, and one contingent value right (CVR) per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata's lead product DALVANCETM are achieved.
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), IRWD: 15.00 (+0.09), CBST: 96.31 (+0.04), PFE: 30.95 (-0.70)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), MDT: 72.52 (-1.25), SLXP: 103.36 (-2.79), SNY: 45.16 (-1.05)
Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), SWKS: 69.10 (-0.98), AKRX: 41.24 (+0.38), JAZZ: 165.12 (-8.09), SLXP: 103.36 (-2.79), AAPL: 109.73 (-1.89), ATHM: 36.03 (-0.09)
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata
PR Newswire - Fri Oct 31, 3:15PM CDT
Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
with respect to Actavis' pending acquisition of Durata. DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Durata Therapeutics, Inc. -- DRTX
GlobeNewswire - Wed Oct 29, 1:02PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Illinois Circuit Court on behalf of all common stockholders of Durata Therapeutics, Inc. ("Durata" or the "Company"
(Nasdaq RTX) opposing the proposed acquisition of Durata by Actavis plc ("Actavis" . DRTX: 24.16 (+0.41)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis
Business Wire - Tue Oct 14, 11:37AM CDT
Levi & Korsinsky is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or "the Company"
(NASDAQ: DRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Actavis (NYSE:ACT). DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of the Company
Business Wire - Sat Oct 11, 6:05AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc. ("Durata" or the "Company"
(Nasdaq: DRTX) relating to the proposed acquisition by Actavis plc. DRTX: 24.16 (+0.41)
DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics Inc. (DRTX) Over the Proposed Sale of the Company to Actavis plc (ACT)
PR Newswire - Fri Oct 10, 5:45PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or the "Company"
(NasdaqGM: DRTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Actavis plc for approximately $675 million. The Company's stockholders will only receive $23.00 for each share of Durata common stock they own, when according to Yahoo! Finance at least one analyst has set a price target of $26.00 for the Company. The deal price might be $5.00 higher based on a contingency-milestone basis. DRTX: 24.16 (+0.41)
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Fri Oct 10, 4:31PM CDT
Rigrodsky & Long, P.A.:
DRTX: 24.16 (+0.41), ACT: 259.00 (-4.00)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Oct 10, 4:25PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Durata Therapeutics, Inc. (NASDAQ: DRTX), ("Durata" or the "Company"
relating to the proposed buyout of the Company by Actavis plc ("Actavis" . DRTX: 24.16 (+0.41)
Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)
GlobeNewswire - Fri Oct 10, 1:04PM CDT
Durata Therapeutics (Nasdaq
RTX) today announced a summary of presentation data from its recently launched product, DALVANCE(TM) (dalbavancin) for injection. The data were presented in five posters at IDWeek 2014, which took place from October 8-11, 2014 in Philadelphia, PA. Among the findings, a study of pharmacokinetic activity in bone and associated tissues demonstrated that dalbavancin accumulates in bone and supports further study in patients with osteomyelitis and prosthetic joint infections. A separate analysis showed patients with ABSSSI who were treated with dalbavancin had similar clinical success rates to those treated with IV vancomycin alone, as well as a tendency to have fewer adverse events and less nephrotoxicity compared to patients who received IV vancomycin for greater-than or equal to10 days. An examination of ASO and DNase-B titers in patients with streptococcal skin infections in the dalbavancin DISCOVER program was also presented. DRTX: 24.16 (+0.41)
Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 2:52PM CDT
Healthcare companies have been completing merger and acquisitions this year at record pace to counter ongoing patent cliff troubles, as well as political gridlock in the U.S. over corporate tax reform. Activist investor Bill Ackman and his hedge...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), VRX: 138.71 (-0.18), ACT: 259.00 (-4.00), SLXP: 103.36 (-2.79)
